Gempharmatech Co. Ltd. A Market Cap ($1.96 Billion)
Market Cap & Net Worth: Gempharmatech Co. Ltd. A (688046)
Gempharmatech Co. Ltd. A market cap. Gempharmatech Co. Ltd. A (SHG:688046) has a market capitalization of $1.96 Billion (CN¥13.41 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #6013 globally and #1124 in its home market, demonstrating a 14.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gempharmatech Co. Ltd. A's stock price CN¥32.70 by its total outstanding shares 410000000 (410.00 Million). Also see Gempharmatech Co. Ltd. A operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Gempharmatech Co. Ltd. A Market Cap History (2022–2026)
Gempharmatech Co. Ltd. A market cap history from 2022 to 2026. Data shows growth from $1.42 Billion to $1.96 Billion (13.83% CAGR). Check 688046 share price today for real-time trading data and today's change.
Gempharmatech Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gempharmatech Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 688046 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.12x
Gempharmatech Co. Ltd. A's market cap is 1.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.02x
Gempharmatech Co. Ltd. A's market cap is 7.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.42 Billion | $516.55 Million | $164.67 Million | 2.74x | 8.60x |
| 2023 | $1.19 Billion | $622.19 Million | $158.91 Million | 1.91x | 7.49x |
| 2024 | $770.95 Million | $686.84 Million | $109.82 Million | 1.12x | 7.02x |
Competitor Companies of 688046 by Market Capitalization
Companies near Gempharmatech Co. Ltd. A in the global market cap rankings as of November 9, 2026. Also see Gempharmatech Co. Ltd. A balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Gempharmatech Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Gempharmatech Co. Ltd. A (2022–2026)
Market capitalization of Gempharmatech Co. Ltd. A from 2022 to today. Between 2022 and today, Gempharmatech Co. Ltd. A's market cap moved from $1.42 Billion to $ 1.96 Billion, with a yearly change of 13.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.96 Billion | +112.89% |
| 2025 | CN¥921.54 Million | +19.53% |
| 2024 | CN¥770.95 Million | -35.20% |
| 2023 | CN¥1.19 Billion | -16.04% |
| 2022 | CN¥1.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Gempharmatech Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.96 Billion USD |
| MoneyControl | $1.96 Billion USD |
| MarketWatch | $1.96 Billion USD |
| marketcap.company | $1.96 Billion USD |
| Reuters | $1.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more